Vasodilating properties of a new non-steroidal antiinflammatory drug, nitroflurbiprofen, on rat aortic rings

Pharmacological Research

Volumn 33, Issue 4-5, 1996, Pages 239-244

  Adami, Alessandra ^b   Cuzzolin, Laura ^b   Minuz, Piero ^b   Crivellente, Federica ^b   Lechi, Alessandro ^b   Benoni, Giuseppina ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE

Author keywords

Aortic rings; Nitroflurbiprofen; Rat; Vasodilation

Indexed keywords

ADRENALIN; CYSTEINE; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GLYCERYL TRINITRATE; METHYLENE BLUE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYHEMOGLOBIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0008803585     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0033     Document Type: Article

References (14)

1. 1. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel NSAID derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 173-9.
2. 2. Mariotto S, Cuzzolin L, Adami A, Del Soldato P, Suzuki H, Benoni G. Effect of a new non-steroidal antiinflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. Br J Pharmacol 1995; 115: 225-6.
3. 3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium derived relaxing factor. Nature 1987; 327: 524-6.
4. 4. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983; 306: 174-6.
5. 5. Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. Boca Raton: CRC Press, 1990: 1-215.
6. 6. Salvemini D, Mollace V, Pistelli A, Anggard E, Vane J. Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by E. coli lipopolysaccharide. Proc Natl Acad Sci USA 1992; 89: 982-6.
7. 7. Chung SJ, Fung HL. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther 1990; 253: 614-9.
8. 8. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989; 257: 1235-9.
9. 9. Carroll MA, Schwartzman M, Capdevila J, Falck JR, McGiff JC. Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol 1987; 138: 281-3.
10. 10. Mitchell JA, Cirino G, Akarasereenont P, Wallace JL, Flower RJ, Vane J. Flurbinitroxybutylester, a novel antiinflammatory drug devoid of ulcerogenic activity, inhibits cyclo-oxygenase-1 and cyclo-oxygenase-2. Can J Physiol Pharmacol 994; 72: 270.
11. 11. Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res 1987; 9: 145-58.
12. 12. Salvemini D, Pistelli A, Vane J. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells. Br J Pharmacol 1993; 108: 162-9.
13. 13. Ahlner J, Andersson RGG, Torfgard K, Axelsson KL. Organic nitrate esters: clinical use and mechanism of actions. Pharmacol Rev 1991; 43: 351-423.
14. 14. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance and strategies for prevention. Ann Intern Med 1991; 114: 667-77.